Figure 1
Perindopril dosage. During the one-year treatment period, the mean perindopril dose in the (+) anti-AT1-AR and (−) anti-AT1-AR group was 3.3 ± 0.1 mg Qd /day and 2.9 ± 0.1 mg Qd/day (P <0.05), respectively. Perindopril (4 mg) was administered to patients with (+) anti-AT1-AR at significantly higher doses than patients with (−) anti-AT1-AR (P < 0.05, 64.6% vs. 44.6%). These results suggest that the patients with (+) anti-AT1-AR are more tolerant to perindopril than those that do not express these autoantibodies.